Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Earnings Data
Report Date
Feb 19, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.82Last Year’s EPS
-0.88Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Kymera Therapeutics reported a successful quarter with notable advancements in its STAT6 and IRF5 programs and strategic partnerships. The financial position remains strong, with a clear path forward for its pipeline. However, concerns about high expenses and data limitations from the Phase Ib trial, along with the challenge of placebo effects in trials, present areas of caution.Company Guidance
Successful Advancement of STAT6 Program
Kymera completed the Phase Ib trial for KT-621 in AD patients and initiated two Phase IIb trials, BROADEN2 in AD and BREADTH in asthma, with impressive progress and data expected soon.
New Partnership with Gilead
Kymera entered into a partnership with Gilead to advance the CDK2 oncology molecular glue program, which is expected to have broad potential in breast cancer and other solid tumors.
Strong Financial Position
Kymera ended the quarter with a cash balance of $978.7 million, providing a runway into the second half of 2028, excluding unearned milestones from collaborations with Sanofi and Gilead.
Progress in IRF5 Program
Kymera unveiled the IRF5 program with robust preclinical data presented at the American College of Rheumatology Annual Meeting, indicating potential in lupus, RA, and other diseases.
Pipeline Expansion and Execution
Kymera is advancing its earlier-stage undisclosed immunology pipeline and initiated KT-579 IND-enabling studies, with plans to start clinical trials early in 2026.
KYMR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KYMR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $59.72 | $59.91 | +0.32% |
Aug 11, 2025 | $40.62 | $37.68 | -7.24% |
May 09, 2025 | $30.77 | $30.07 | -2.27% |
Feb 27, 2025 | $35.36 | $30.25 | -14.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kymera Therapeutics (KYMR) report earnings?
Kymera Therapeutics (KYMR) is schdueled to report earning on Feb 19, 2026, Before Open (Confirmed).
What is Kymera Therapeutics (KYMR) earnings time?
Kymera Therapeutics (KYMR) earnings time is at Feb 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KYMR EPS forecast?
KYMR EPS forecast for the fiscal quarter 2025 (Q4) is -0.82.